Nebivolol
Bystolic, Nebivolol, Vyduo (nebivolol) is a small molecule pharmaceutical. Nebivolol was first approved as Bystolic on 2007-12-17. It is used to treat malignant hypertension in the USA. It is known to target beta-3 adrenergic receptor, beta-2 adrenergic receptor, and beta-1 adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| cardiovascular diseases | D002318 |
Trade Name
FDA
EMA
Bystolic, Nebivolol (discontinued: Nebivolol)
CombinationsVyduo (discontinued: Byvalson)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| bystolic | New Drug Application | 2024-08-23 |
| nebivolol | ANDA | 2025-03-28 |
| nebivolol hydrochloride | ANDA | 2023-07-11 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
ATC Codes
C: Cardiovascular system drugs
— C07: Beta-adrenergic blocking agents
— C07A: Beta blocking agents
— C07AB: Beta blocking agents, selective
— C07AB12: Nebivolol
— C07B: Beta blocking agents and thiazides
— C07BB: Beta blocking agents, selective, and thiazides
— C07BB12: Nebivolol and thiazides
— C07F: Beta blocking agents, other combinations
— C07FB: Beta blocking agents and calcium channel blockers
— C07FB12: Nebivolol and amlodipine
— C09: Agents acting on the renin-angiotensin system
— C09D: Angiotensin ii receptor blockers (arbs), combinations
— C09DX: Angiotensin ii receptor blockers (arbs), other combinations
— C09DX05: Valsartan and nebivolol
HCPCS
No data
Clinical
Clinical Trials
123 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 2 | 6 | 16 | 35 | 17 | 74 |
| Heart failure | D006333 | EFO_0003144 | I50 | — | — | 2 | 9 | 5 | 16 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | 5 | — | 5 |
| Diastolic heart failure | D054144 | EFO_1000899 | I50.30 | — | — | — | 4 | — | 4 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | — | — | 1 | 2 | 3 |
| Prehypertension | D058246 | — | — | — | — | — | 3 | — | 3 |
| Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | — | — | 1 | 2 | 3 |
| Coronary artery disease | D003324 | — | I25.1 | — | 1 | 1 | 2 | — | 3 |
| Left ventricular dysfunction | D018487 | — | — | — | — | 2 | 1 | — | 3 |
| Blood pressure | D001794 | EFO_0004325 | — | — | — | — | 1 | 1 | 2 |
Show 35 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | U07.1 | — | — | 1 | — | 1 | 2 |
| Myocardial bridging | D054084 | — | — | — | 2 | 1 | — | — | 2 |
| Ventricular dysfunction | D018754 | — | — | — | — | 2 | — | — | 2 |
| Marfan syndrome | D008382 | Orphanet_558 | Q87.4 | — | — | 1 | — | — | 1 |
| Pathologic dilatation | D004108 | — | — | — | — | 1 | — | — | 1 |
| Arachnodactyly | D054119 | — | — | — | — | 1 | — | — | 1 |
| Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | — | 1 | — | — | 1 |
| Duchenne muscular dystrophy | D020388 | EFO_0000429 | — | — | — | 1 | — | — | 1 |
| Muscular dystrophies | D009136 | EFO_0000757 | G71.0 | — | — | 1 | — | — | 1 |
| Peripheral arterial disease | D058729 | EFO_0004265 | — | — | — | 1 | — | — | 1 |
Show 8 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Essential hypertension | D000075222 | — | I10 | — | 1 | — | — | 1 | 2 |
| Ischemic stroke | D000083242 | — | — | — | 1 | — | — | — | 1 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | — | — | — | 1 |
| Ischemia | D007511 | EFO_0000556 | — | — | 1 | — | — | — | 1 |
| Ocular hypertension | D009798 | EFO_1001069 | H40.0 | — | 1 | — | — | — | 1 |
| Glaucoma | D005901 | EFO_0000516 | H40 | — | 1 | — | — | — | 1 |
| Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
| Pure autonomic failure | D054970 | — | — | 1 | — | — | — | 1 | 2 |
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | 1 | — | — | — | — | 1 |
| Fatty liver | D005234 | EFO_0003934 | — | 1 | — | — | — | — | 1 |
| Idiopathic pulmonary fibrosis | D054990 | — | J84.112 | 1 | — | — | — | — | 1 |
| Pulmonary fibrosis | D011658 | — | J84.10 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | — | 1 | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | — | 1 | 1 |
| Exercise test | D005080 | EFO_0004328 | — | — | — | — | — | 1 | 1 |
| Renal insufficiency | D051437 | — | N19 | — | — | — | — | 1 | 1 |
| Kidney transplantation | D016030 | — | — | — | — | — | — | 1 | 1 |
| Hot flashes | D019584 | — | — | — | — | — | — | 1 | 1 |
| Heart rate | D006339 | EFO_0004326 | — | — | — | — | — | 1 | 1 |
| Sexual arousal | D000083942 | — | — | — | — | — | — | 1 | 1 |
| Systolic murmurs | D054160 | — | R01.1 | — | — | — | — | 1 | 1 |
| Shy-drager syndrome | D012791 | EFO_1001050 | — | — | — | — | — | 1 | 1 |
Show 2 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Nebivolol |
| INN | nebivolol |
| Description | 2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol] is a member of the class of chromanes that is 2,2'-iminodiethanol in which one hydrogen attached to each hydroxy-bearing carbon is replaced by a 6-fluorochroman-2-yl group. It is an organofluorine compound, a secondary amino compound, a secondary alcohol, a diol and a member of chromanes. |
| Classification | Small molecule |
| Drug class | beta-blockers (propranolol type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1 |
Identifiers
| PDB | — |
| CAS-ID | 99200-09-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL434394 |
| ChEBI ID | 64019 |
| PubChem CID | 71301 |
| DrugBank | DB04861 |
| UNII ID | 030Y90569U (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
ADRB3
ADRB3
ADRB2
ADRB2
ADRB1
ADRB1
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Nebivolol
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,684 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,583 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use